￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the long-term safety and treatment duration of Pitobrutinib/Pitobrutinib (Jepali)

2026-02-01 22:25:32

Check Details
The efficacy of talazoparib (Tazena) in patients with prostate cancer TP gene mutation

2026-02-01 22:25:32

Check Details
Crizotinib price decline and interpretation of market reference information

2026-02-01 22:25:32

Check Details
A safety study on whether aprocitentan can be used in combination with other drugs

2026-02-01 22:25:32

Check Details
Whether Tirzepatide can be reimbursed by medical insurance and cost explanation

2026-02-01 22:25:32

Check Details
Clinical verification and scope of application of the efficacy and role of Pitobrutinib/Pitobrutinib (Zepali)

2026-02-01 22:25:32

Check Details
Talazoparib (Tazena) dosage and usage standards and individualized adjustment methods

2026-02-01 22:25:32

Check Details
Why the price of Crizotinib is high and cost analysis

2026-02-01 22:25:32

Check Details
Revumenib-REVUFORJ analysis of different dosages, treatment schedules and patient medication recommendations

2026-02-01 22:25:32

Check Details
Analysis of the pharmacological effects, indications and clinical efficacy of Guanfacine in attention deficit hyperactivity disorder

2026-02-01 22:25:32

Check Details
Detailed analysis of pacritinib’s medical insurance price, reimbursement policy and patient purchase reference

2026-02-01 22:25:32

Check Details
Letermovir tablets (Letermovir) medical insurance inclusion status, reimbursement conditions and cost reference instructions

2026-02-01 22:25:32

Check Details
Category
相关知识